VectivBio Holding AG

General Information
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our product pipeline is focused on rare gastrointestinal, or GI, disorders. Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS. Based on our preclinical and clinical data to date, we believe that apraglutide has the potential to advance the treatment of SBS intestinal failure. Apraglutide is being evaluated in a global Phase 3 clinical trial to treat patients with SBS-IF. SBS is a malabsorption disorder caused by the loss of functional small intestine; symptoms include diarrhea, dehydration, malnutrition and weight loss. SBS occurs in adults as a consequence of irreparable GI damage caused by physical trauma, Crohn’s disease, ulcerative colitis, ischemia or cancer resulting in surgery to remove large portions of the small intestine or colon. 
(Note: VectivBio priced its IPO on April 8, 2021, at $17 – the mid-point of its $16-to-$18 range – on 7.5 million shares to raise $127.5 million.)
Employees: 25
Founded: 2019
Contact Information
Address Aeschenvorstadt 36 4051 Basel Switzerland
Phone Number +41 61 551 30 30
Web Address
View Prospectus: VectivBio Holding AG
Financial Information
Market Cap $578.17mil
Revenues $0 mil (last 12 months)
Net Income $-59.94 mil (last 12 months)
IPO Profile
Symbol VECT
Exchange NASDAQ
Shares (millions): 7.5
Price range $17.00 - $17.00
Est. $ Volume $127.5 mil
Manager / Joint Managers BofA Securities/ SVB Leerink/ Credit Suisse
CO-Managers LifeSci Capital
Expected To Trade: 4/9/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change